(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Chinese fossils reveal a primordial burst of animal evolution - 2Instructions to Pick the Best Album Rates for Your Investment funds
- 3Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- 4The Best 10 Innovation Advancements of the Year
- 5Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Good ways to respond if your kid brings home less-than-ideal grades
- Remote Headphones: Upgrade Your Sound Insight
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- How did I get my own unique set of fingerprints?
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
